Didactics

The fellowship program involves a series of didactic classes designed to provide basic skills in clinical design, pharmacokinetics and pharmacogenetics, biomarker assessment and development, as well as ethical issues in clinical research. Didactic courses take place within a rich academic research environment that involves the study of therapeutics in humans of all ages and ethnicities.

Friday Didactics Schedules

Schedule is subject to change.

January 19, 2024

Statistical Analysis 1: Continuous Data
Paul Berg, MS & Forrest Williamson, PhD, MS

January 26, 2024

Statistical Analysis 2: Categorical Data
Paul Berg, MS and Forrest Williamson, PhD, MS

February 2, 2024

Statistical Tests and Model Building
Paul Berg, MS and Forrest Williamson, PhD, MS

February 9, 2024

Human Studies 1 (Design)
Paul Berg, MS and Forrest Williamson, PhD, MS

February 16, 2024

Human Studies 2 (Analysis/Interpretations)
Paul Berg, MS and Forrest Williamson, PhD, MS

February 23, 2024

Statistical Methods for Clinical Pharmacology
Paul Berg, MS and Forrest Williamson, PhD, MS

February 3, 2023

Introduction/Phase 1
Eric Benson, MD and Tom Callaghan, MD, PhD

February 10, 2023

Toxicology
Thomas Jones, PhD

February 17, 2023

Application of Artificial Intelligence and Machine Learning for Precision Medicine
Workshop by Indiana CTSI WGHI Winter Retreat

February 24, 2023

NO DIDACTIC - SYMPOSIUM

March 3, 2023

Biomarker Development
Tom Callaghan, MD, PhD

March 10, 2023

Precision Oncology Trials
Tom Callaghan, MD, PhD

March 17, 2023

NO DIDACTIC - SPRING BREAK

March 24, 2023

Preclinical Pharmacology
Andrew Dahlem, DVM (hc), PhD

March 31, 2023

Late Phase Trial Development
William Macias, MD, PhD

April 7, 2023

Role of Modeling
Robert Stratford, PhD

April 14, 2023

Ethical Considerations and Rare Diseases
Tim Franson, MD

April 21, 2023

Special Populations: Gender, Disease, Age, and Other Covariates

Richard Bergstrom, PhD

April 28, 2023

Special Populations:Hepatic/Renal Impaired States

Michael Eadon, MD

August 25, 2023

Drug Measurement 1 -- Small Molecules
Lais Da Silva, PhD

September 1, 2023

Drug Measurement 2 -- Macromolecular Drugs
Ronald Bowsher, PhD

September 8, 2023

CH 1, 2 Therapeutic Relevance; Fundamental Concepts and Terminology; Appendix A Assessment of AUC
Richard Bergstrom, PhD and Brian Overholser, PharmD

September 15, 2023

CH 3 Kinetics Following and Intravenous Bolus Dose: Appendix H Mean Residence Time
Kevin Sowinski, PharmD

September 22, 2023

CH 4, 19 Membranes and Distribution; Distribution Kinetics Appendix B Ionization an pH Partition Hypothesis; Appendix C Distribution of Drugs Extensively Bound to Plasma Proteins
Sara Quinney, PharmD, PhD

September 29, 2023

CH 5 Elimination; Appendix D Plasma-to-Blood Concentration Ratio; Appendix E Well-Stirred Model of Hepatic Clearance
Brian Overholser, PharmD

October 6, 2023

CH 6, 7 Kinetics Following an Extravascular Dose; Absorption; Appendix F Absorption Kinetics; Appendix G Wagner-Nelson Method
Kevin Sowinski, PharmD

October 13, 2023

CH 10 Constant-Rate Input
Lais Da Silva, PhD

October 20, 2023

CH 8, 9 Response Following a Single Dose; Therapeutic Window
Brian Overholser, PharmD

October 27, 2023

CH 11, 18 Multiple Dose Regimens; Initiating and Managing Therapy
Richard Bergstrom, PhD

November 3, 2023

CH 17, 20 Metabolite and Drug Response; Drug Interaction
Lais Da Silva, PhD

November 10, 2023

CH 12, 13 Variability; Genetics; Age, Weight, Gender, Disease
Sara Quinney, PharmD, PhD

November 17, 2023

CH 14, 15 Variability; Genetics; Age, Weight, Gender, Disease
Sara Quinney, PharmD, PhD

November 24, 2023

NO CLASS - THANKSGIVING BREAK

December 1, 2023

CH 16, Nonlinearities
Sara Quinney, PharmD, PhD

December 8, 2023

CH 21, 22 Protein Drugs; Predictions of Human PK from Preclinical
Richard Bergstrom, PhD

December 15, 2023

TAKE HOME FINAL EXAMINATION

January 21, 2022
Univariate Continuous Statistical Data Analysis
Forrest Williamson, PhD

January 28, 2022
Univariate Categorical Statistical Data Analysis
Forrest Williamson, PhD

February 4, 2022
Statistical Tests and Model Building
Forrest Williamson, PhD
Paul H Berg, MS

February 11, 2022
Human Studies 1 (Design)
Paul H Berg, MS

February 25, 2022
Human Studies 2 (Analysis/Interpretations)
Forrest Williamson, PhD
Paul H Berg, MS

March 4, 2022
Statistical Methods Useful in Clinical Pharmacology
Paul H Berg, MS

August 12, 2022
Pharmacogenetics: General Concepts
Todd Skaar, PhD

August 19, 2022
Clinical Relevance of CYP2Cs Genetic Polymorphism I
Zeruesenay Desta, PhD

August 23, 2022
Genotyping and Sequencing I (SPECIAL DAY - HELD ON TUESDAY IN LIEU OF SEMINAR)
Todd Skaar, PhD

August 26, 2022
Genotyping and Sequencing II
Todd Skaar, PhD

September 2, 2022
Clinical Relevance of CYP2Cs Genetic Polymorphism II
Zeruesenay Desta, PhD

September 9, 2022
Pharmacogenetics of Phase II Metabolism: Glucuronidation
Zeruesenay Desta, PhD

September 16, 2022
Pharmacogenetics of Phase II Metabolism: N-acetylation and Thiopurine Methyltransferase
Zeruesenay Desta, PhD

September 23, 2022
Pharmacogenetics of CYP2D6
Todd Skaar, PhD

September 30, 2022
Pharmacogenomics of CYP3A
Todd Skaar, PhD

October 7, 2022
GWAS, Polygenic Models, and Secondary Big Data Analysis
Nick Powell, PharmD

October 14, 2022
Phenoconversions
Tom Callaghan, MD, PhD

October 21, 2022
Clinical Implementation of Pharmacogenomic Testing
Emma Tillman, Pharm D, PhD

October 28, 2022
Clinical Pharmacogenomics Testing
Victoria Pratt, PhD, FACMG

November 4, 2022
Opioid Pharmacodynamics
Tom Callaghan, MD, PhD

November 11, 2022
QT Prolongation
Brian Overholser, PharmD, FDCP

November 18, 2022
Pharmacogenomics of Drug Transporters
Michael Eadon, MD

November 25, 2022
No Didactics - Day After Thanksgiving Holiday

December 2, 2022
Pharmacogenomics of Hypertension Therapies
Michael Eadon, MD

December 9, 2022
PGx Extraction
Tyler Shugg, PharmD, PhD

December 16, 2022
Cancer Somatic Genomics
Patrick Kiel, PharmD

April 16, 2021
Special Populations - Pregnancy
Sara K. Quinney, PhD

April 23, 2021
Special Populations - Geriatric
J. Thomas Callaghan, MD, PhD

April 30, 2021
Special Populations - Hepatic / Renal
Michael T. Eadon, MD

August 17, 2021
Drug Measurement 1 - small molecule
Andi Masters, MS

September 3, 2021
Drug Measurement 2 - macromolecular drugs
Ronald Bowsher, PhD

September 10, 2021
Ch 1, 2 Therapeutic Relevance; Fundamental Concepts and Terminology;
Appendix A Assessment of AUC
Rich Bergstrom, PhD/Brian Overholser, PharmD

September 17, 2021
Ch 3 Kinetics Following and Intravenous Bolus Dose
Appendix H Mean Residence Time
Kevin Sowinski, PharmD

September 24, 2021
Ch 4, 19 Membranes and Distribution; Distribution Kinetics
Appendix B Ionizabion an pH Partition Hypothesis; Appendix C
Distribution of Drugs Extensively Bound to Plasma Proteins
Sara Quinney, PhD

October 1, 2021
CH 5 Elimination; Appendix D Plasma-to-Blood Concentration Ratio;
Appendix E Well-Stirred Model of Hepatic Clearance
Brian Overholser, PharmD

October 8, 2021
CH 6, 7 Kinetics Following an Extravascular Dose; Absorption;
Appendix F Absorption Kinetics; Appendix G Wagner-Nelson
Kevin Sowinski, PharmD

October 15, 2021
CH 10 Constant-Rate Input
Robert Stratford, PhD

October 22, 2021
CH 8, 9 Response Following a Single Dose; Therapeutic Window
Brian Overholser, PharmD

October 29, 2021
CH 11, 18 Multiple Dose Regimens; Initiating and Managing
Rich Bergstrom, PhD

November 5, 2021
CH 17, 20 Metabolite and Drug Response; Drug Interaction
Robert Stratford, PhD

November 12, 2021
CH 12, 13 Variability; Genetics; Age, Weight, Gender, Disease
Sara Quinney, PhD

November 19, 2021
CH 14, 15 Variability; Genetics; Age, Weight, Gender, Disease
Sara Quinney, PhD

November 26, 2021
NO CLASS - THANKSGIVING BREAK

December 3, 2021
CH 16, Nonlinearities
Sara Quinney, PhD

December 10, 2021
CH 21, 22 Protein Drugs; Predictions of Human PK from
Rich Bergstrom,PhD

December 17, 2021
TAKE HOME FINAL EXAM

January 10, 2020
Statistical Analysis 1: Continuous Data
Forrest Williamson, PhD

January 17, 2020
Statistacal Analysis 2 Categorical Data
Forrest Williamson, PhD

January 24, 2020
Statistical Tests and Model Building
Fanni Natanegara, PhD

January 30, 2020
Human Studies 1 (Design)
Paul H. Berg, MS

February 7, 2020
Human Studies 2 (Analysis/Interpretations)
Fanni Natanegara, PhD

February 14, 2020
Statistical Methods for Clinical Pharmacology
Paul H. Berg, MS

August 14, 2020
Pharmacogenetics: General Concepts
Todd Skaar, PhD

August 21, 2020
Clinical Relevance of CYP2C9 and CYP2C19 Genetic Polymorphism
Zeruesenay Desta, PhD

August 28, 2020
Genotyping and Sequencing I
Todd Skaar, PhD

September 4, 2020
Clinical Relevance of CYP2Cs Genetic Polymorphism
Zeruesenay Desta, PhD

September 11, 2020
Genotyping and Sequencing II
Todd Skaar, PhD

September 18, 2020
Pharmacogenetics of Phase II Metabolism: Glucuronidation
Zeruesenay Desta, PhD

September 25, 2020
Pharmacogenetics of Phase II Metabolism: N-acetylation and Thiopurine Methyltransferase
Zeruesenay Desta, PhD

October 2, 2020
Pharmacogenetics of CYP2D6
Todd Skaar, PhD

October 9, 2020
Pharmacogenomics of CYP3A
Todd Skaar, PhD

October 16, 2020
Phenoconversions
Tom Callaghan, MD, PhD

October 23, 2020
No Didactics

October 30, 2020
No Didactics

November 6, 2020
Opioid Pharmacodynamics
Tom Callaghan, MD, PhD

November 13, 2020
QT Prolongation
Brian Overholser, PharmD, FDCP

November 20, 2020
Pharmacogenomics of Drug Transporters
Michael Eadon, MD

December 4, 2020
Pharmacogenomics of Hypertension Therapies
Michael Eadon, MD

December 11, 2020
Clinical Pharmacogenomics Testing
Victoria Pratt, PhD, FACMG